Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Projected to Reach US$1.7 bn by 2024
Europe to Lead Global Market with a CAGR of 30.80% 2016-2024
On the basis of type, the global market is segmented into serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others. Out of these, the hepatic fibrosis biomarkers segment is expected to progress at a phenomenal CAGR of 32.7% between 2016 and 2024. The growth of this segment will be attributable to the high accuracy and efficacy provided by these biomarkers.
In terms of geography, the overall market is fragmented into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. The report predicts that North America is likely to hold a significant share in the overall market in the coming years due to the emergence of NASH health care sector. However, Europe is expected to dominate the global market as it is estimated to progress at a CAGR of 30.80% between 2016 and 2024.
Read Report overview @ https://www.transparencymarketresearch.com/non-alcoholic-steatohepatitis-biomarkers-market.html
Preference for Non-invasive Procedures Contributes to Soaring NASH Biomarkers Market Revenue
The rising prevalence of non-alcoholic liver diseases has been the primary growth driver for the NASH biomarkers market. The growing number type 2 diabetics are estimated to boost the overall market as this pool is population is prone to NAFLAD along with other liver diseases. The market is also anticipated to be driven by the changing lifestyles that are characterized by smoking, poor eating habits, and lack of exercise. The smothering rise in air pollution is also expected to drive the global NASH biomarkers market in the coming years.
The growing demand for non-invasive diagnostic techniques to determine the complication and stage of the liver diseases have also augmented the demand for NASH biomarkers. Due to the ability of reproduce the results, these biomarkers have become the preferred choice for diagnosing and monitoring NASH. The market is also slated to find an adequate drive in treating the unmet medical needs of NASH as the liver-related diseases are on the rise. Demand for low-cost diagnostic techniques as compared to liver biopsy, which requires hospital stay and anesthesia are also likely to encourage the growth of the global market.
Lack of Accuracy of Individual Biomarkers Restrains Market Growth
The limitations pertaining to the accuracy and sensitivity in determining the results in the key challenge for the players operating in the global NASH biomarkers market. Thus, the questionable accuracy of individual biomarkers and their panels is anticipated to restrain the growth of the overall market. Furthermore, the global NASH biomarkers market is also challenged by the overlapping results for other metabolic disorders. Since these biomarkers deliver overlapping results for metabolic diseases such as glycogenic hepatopathy, diabetic hepatosclerosis, and Wilson diseases the reliability of the biomarkers remains under question.This review is based on Transparency Market Research’s report, titled “Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”
Request Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=18650
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453
TMR Blog: http://www.theglobalhealthnews.com/
This release was published on openPR.
Permanent link to this press release:
You can edit or delete your press release Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Projected to Reach US$1.7 bn by 2024 here
News-ID: 852003 • Views: 136
More Releases from Transparency Market Research
Impact of Outbreak of COVID-19 on Medical Education Market : Global Industry Ana …
Transparency Market Research (TMR) has published a new report on the medical education market for the period of 2019–2027. According to the report, the global medical education market was valued at nearly US$ 31 Bn in 2018, and is projected to expand at a CAGR of more than 4% from 2019 to 2027. Rise in the number of medical schools and increase in cost of medical education are the
Healthcare BI Platform Market Companies Analysis, Advancement and Precise Outloo …
In an intensely competitive healthcare business intelligence (BI) platform market, large players are aggressively focused on expanding their geographical outreach, says Transparency Market Research (TMR) in a new market intelligence report. These large players are leveraging the cloud business model to provide healthcare BI solutions that can be accessed irrespective of location. Apart from this, savvy players are entering into partnerships with hospital groups and healthcare bodies to integrate healthcare BI
Substance Abuse Treatment Market News Research Report 2024
A recent report by Transparency Market Research on the substance abuse treatment market in the U.S. states that the competitive landscape is highly fragmented. This is because around 242 companies compete against one another in it. This also makes overall competition stiff. Some of the companies that have beat competition to emerge as leading players in the market are Pfizer Inc., Alkermes Plc, GlaxoSmithKline Plc., and Purdue Pharma LP. Their
Clinical Oncology Next Generation Sequencing Market is Thriving Worldwide By Siz …
Clinical Oncology Next Generation Sequencing: Introduction Next generation sequencing for tumor and germline DNA is required for oncology screening for therapeutic application. Rise in burden of cancer increases the need for early detection of the condition to carry out the generate target therapy. Companies are investing to develop technologically advanced devices/solutions for precision detection. In 2012, Oxford Nanopore had launched the GridION sequencing platform, which can sequence a human genome in 15
More Releases for NASH
NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market
Overview of NASH - Opportunity Analysis and Forecasts to 2026
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation
Nonalcoholic Steatohepatitis (NASH) Syndrome - Opportunity Analysis and Forecast …
First described in 1980, Nonalcoholic Steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nonalcoholic Steatohepatitis (NASH) Market Worth US$ 20.0 Billion by 2025
New York, December 12: Market Research Engine has published a new report titled as “Non-Alcoholic Steatohepatitis (NASH) Market by Therapeutics (GFT505, Obeticholic Acid (INT-747), Liraglutide (Victoza) and Simtuzumab, Vitamin E, Pioglitazone, Placebo) - Global Industry Analysis, Trends and Forecast 2016 - 2025” Global Non-Alcoholic Steatohepatitis (NASH) market is expected to cross US$ 20.0 Billion by 2025 growing at a CAGR of more than 10.0% during given forecast period from 2016-2025. Browse Full